Karl Swedberg

Summary

Country: Germany

Publications

  1. ncbi Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock
    Andreas Link
    Klinik fur Innere Medizin III, Universitat des Saarlandes, 66421 Homburg Saar, Germany
    Crit Care 12:R159. 2008
  2. ncbi Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study
    Andreas Link
    Klinik fur Innere Medizin III, Universitatsklinikum des Saarlandes, Kirrberger Strasse, 66421 Homburg Saar, Germany
    Crit Care 12:R111. 2008
  3. ncbi [Erectile dysfunction as cardiovascular risk marker. Role of the renin-angiotensin system]
    M Bohm
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Homburg Saar
    Dtsch Med Wochenschr 133:1313-6. 2008
  4. ncbi Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients
    Michael Bohm
    Klinik für Innere Medizin III Kardiologie, Angiologie, Internistische Intensivmedizin, Universitat des Saarlandes, Kirrberger Strasse, 66424 Homburg Saar, Germany
    Eur Heart J 30:1364-71. 2009
  5. ncbi Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoler
    Michael Bohm
    Department of Cardiology, University of the Saarland, Saarbrucken, Germany
    Circulation 121:1439-46. 2010
  6. ncbi Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    Michael Bohm
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin III, Homburg Saar, Germany
    Lancet 376:886-94. 2010
  7. ncbi Heart rate reduction in cardiovascular disease and therapy
    Jan Christian Reil
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und, Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Kirrberger Strasse, 66421, Homburg Saar, Germany
    Clin Res Cardiol 100:11-9. 2011
  8. ncbi Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
    Michael Bohm
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Kirrberger Str 1, 66424, Homburg Saar, Germany
    Clin Res Cardiol 102:11-22. 2013

Detail Information

Publications8

  1. ncbi Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock
    Andreas Link
    Klinik fur Innere Medizin III, Universitat des Saarlandes, 66421 Homburg Saar, Germany
    Crit Care 12:R159. 2008
    ....
  2. ncbi Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study
    Andreas Link
    Klinik fur Innere Medizin III, Universitatsklinikum des Saarlandes, Kirrberger Strasse, 66421 Homburg Saar, Germany
    Crit Care 12:R111. 2008
    ..The reversible platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban was investigated to preserve platelet number and activation in a prospective open-blinded endpoint evaluation study...
  3. ncbi [Erectile dysfunction as cardiovascular risk marker. Role of the renin-angiotensin system]
    M Bohm
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Homburg Saar
    Dtsch Med Wochenschr 133:1313-6. 2008
  4. ncbi Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients
    Michael Bohm
    Klinik für Innere Medizin III Kardiologie, Angiologie, Internistische Intensivmedizin, Universitat des Saarlandes, Kirrberger Strasse, 66424 Homburg Saar, Germany
    Eur Heart J 30:1364-71. 2009
    ..To investigate the relationship between microalbuminuria (MAU) and atrial fibrillation (AF) and to further evaluate whether the heart rate dependency of MAU in patients without AF is maintained in patients with a history of AF...
  5. ncbi Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoler
    Michael Bohm
    Department of Cardiology, University of the Saarland, Saarbrucken, Germany
    Circulation 121:1439-46. 2010
    ....
  6. ncbi Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    Michael Bohm
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin III, Homburg Saar, Germany
    Lancet 376:886-94. 2010
    ..We aimed to test our hypothesis by investigating the association between heart rate and events in this patient population...
  7. ncbi Heart rate reduction in cardiovascular disease and therapy
    Jan Christian Reil
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und, Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Kirrberger Strasse, 66421, Homburg Saar, Germany
    Clin Res Cardiol 100:11-9. 2011
    ..Heart rate can be easily determined during physical examination of the patient and therefore allows a simple hint on prognosis and efficiency of therapy...
  8. ncbi Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
    Michael Bohm
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Kirrberger Str 1, 66424, Homburg Saar, Germany
    Clin Res Cardiol 102:11-22. 2013
    ..A cut-off value of ≥75 bpm was chosen by the EMEA for approval for the use of ivabradine in chronic heart failure...